Joanna Wykrzykowska


Joanna Wykrzykowska is an interventional cardiologist at the department of Cardiology in the University Medical Center Groningen. Her research focuses on treatment and improving outcomes of ischemic and valvular heartdisease.

Dr Joanna J. Wykrzykowska obtained her doctorate of medicine from Harvard Medical School and Massachusetts Institute of Technology, Boston MA in 2002. She completed her internal medicine residency at the Massachusetts General Hospital and her Cardiology Fellowship at Beth Israel Deaconess Medical Center (both Harvard teaching hospitals). She continued and completed her Interventional Cardiology fellowship at Erasmus MC, Rotterdam NL in 2010 and obtained her PhD in interventional cardiology in 2011 under the supervision of Professor Patrick Serruys. She worked as staff Interventional Cardiologist at the Amsterdam University Medical Center till 2020 where she was the principal investigator of multiple clinical trials, including AIDA trial (published in NEJM).

Since 2020 Dr. Wykrzykowska is an interventional cardiologist and also holds the title of an Associate Professor of Interventional Cardiology at the University Medical Center in Groningen.  Her research focuses on predictors of clinical outcomes using imaging parameters and artificial intelligence techniques in both coronary artery disease and valvular heart disease (aortic stenosis). She is a promotor of 19 PhD candidates and has authored 265 papers in interventional cardiology. Her H-index is 41. She is also a member of the Eurointervention editorial board and is on the faculty of EuroPCR, TCT, London valves, New York valves and ESC congresses.

Current projects:
Ability DM – National Lead PI
Pioneer IV – Steering committee member
Multitalent trial – National Lead PI
Selution de novo – National Lead PI
Matrix-2 – National Lead PI and Steering committee member
Viking trial – Chairman
Selution SR, SOS-AMI, Artemis, Popular Pause, Prove registry– local PI

My projects


Evolut™ EXPAND TAVR II Pivotal Trial

ABILITY Diabetes Global

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellitus Global


Non-inferiority of angiography-derived physiology guidance versus usual care in an All-comers PCI population treated with unrestricted use of the Healing-Targeted Supreme (HT SupremeTM) drug eluting stent and P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy: the PIONEER IV trial

Multivessel TALENT

Full title study: A randomized controlled trial to compare the safety and efficacy of siroliMUs-eLuTIng biodegradable polymer ulTrA-thin stent (SUPRAFLEXTM Cruz) and everolimus-eLuting biodegradable polymer stent (SYNERGYTM) in treatmENT for three-vessel coronary artery disease: Multivessel TALENT